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The treatment of hepatitis C has dramat-
ically improved over the last decade. The
association between pegylated interferon
and ribavirin is the first-line gold stan-
dard but it has some limitations: (i) a
limited efficacy in patients with hepatitis C
virus (HCV) genotype 1 and (ii) an unfa-
vorable side effect profile. Development
of new therapeutic approaches is war-
ranted (Manns et al., 2006). Generally,
the treatment of chronic HCV infection
is focuses (i) to achieve sustained eradica-
tion of HCV [sustained virologic response
(SVR): persistent absence of HCV RNA in
serum 6 months or more after complet-
ing antiviral treatment] and (ii) to prevent
progression to cirrhosis and hepatocellu-
lar carcinoma (HCC). Currently, the most
promising drugs against HCV infection
(genotype 1) are protease inhibitors. They
are peptidomimetic inhibitors of the HCV
non-structural (NS) 3/4A serine protease.
NS3 protease plays an important role in
the HCV life-cycle by causing cleavage of
HCV polyprotein at the NS3-NS4A and
other downstream junctions (Tomei et al.,
1993; Romano et al., 2012).
Telaprevir and boceprevir were
approved by the Food and Drug
Administration (FDA) in May 2011 for the
treatment of HCV genotype 1 in combi-
nation with peginterferon and ribavirin
(triple therapy) in adult patients with
compensated liver disease, including cir-
rhosis, who have not been treated before
or who have failed a previous treatment
(Asselah, 2012; Popescu et al., 2012).
In Italy, telaprevir and boceprevir were
approved in December 2012 after a
complicated prescriptive pathway (defini-
tion of the AIFA—Agenzia Italiana del
FArmaco—register for the intensive moni-
toring, identification of authorized centers
for prescription, definition of dispensing
modalities).
The first prescriptions of telaprevir
and boceprevir in the Local Sanitary
Agency (LSA) Naples 3 South Italy (i.e.,
LSA, NA 3 South, 1.200.000 inhabitants,
Campania Region) were done in March
2013. Currently (June 2013), patients
treated with the protease inhibitors are
87: 58 with telaprevir (51 naive and 7
null responders) and 29 with bocepre-
vir (24 naive and 5 null responders).
During the observed 4 months, 8 treat-
ment interruptions have occurred, all with
telaprevir. Reasons for interruption were:
2 cases of severe anemia, 1 case of severe
allergy with rush. Five patients were lost
at follow-up. No interruption occurred
among patients receiving boceprevir. This
first survey of pharmacoutilization clearly
shows that telaprevir is more frequently
prescribed than boceprevir.
Probably, this is due to different therapy
protocols. In fact telaprevir is indicated in
triple therapy for the first 12 weeks fol-
lowed by a dual therapy (only with pegin-
terferon and ribavirin) for 36 weeks.
Boceprevir is started after 4 weeks of
a dual therapy with peginterferon alfa
and ribavirin. The combination therapy
(boceprevir, peginterferon and ribavirin)
is administered for 24 weeks if the virus
is undetectable at week 8 and 24 or for 44
weeks if the virus is detectable at week 8
but undetectable at week 24.
Both drugs achieve similar SVR rates
but treatment strategies are completely
different. The therapy with telaprevir
appears easier and faster. In this first
4 months, the total pharmaceutical spend-
ing to acquire protease inhibitors for 87
patients was approximately C 1.700.000.
In particular, C 1.350.000 were spent for
telaprevir and C 350.000 for boceprevir.
The choice on a specific protease
inhibitor should weigh several factors
including the treatment strategy, the dura-
tion of therapy, the likelihood of achieving
a SVR, the safety profile and the costs
(Esteban and Buti, 2012). We are really
concerned about the high cost of the ther-
apy with protease inhibitors. In our series
we observed that among patients who
interrupted the treatment 1 was male and
7 female; this could suggest that gender
could be associated with treatment com-
pliance. However, we cannot rule out any
conclusion and studies on large series are
warranted to find predictive factors for
response to protease inhibitors in HCV.
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